The American Recovery and Reinvestment Act of 2009 provided $1.1 billion for comparative effectiveness research (CER). The Patient Protection and Affordable Care Act established the Patient-Centered ...

Comparative effectiveness research has been the target of recurrent criticism in some political circles, with opponents claiming it’s the “gateway to rationing” or it encourages “cookbook medicine.” ...

The goal of comparative effectiveness research is to inform clinical decisions between alternate treatment strategies using data that reflect real patient populations and real-world clinical scenarios ...

The US House of Representatives is considering legislation (HR 485) that would prohibit the use of the quality-adjusted life-year (QALY) and similar measures for coverage and payment determinations ...

A new national initiative in comparative effectiveness research (CER) is part of a broad and long-term evolution toward greater reliance on scientific evidence in clinical practice and medical policy.

Rigorous scientific standards are needed to address the challenge of providing information on the real-world effects of treatments and procedures. With enactment of healthcare reform legislation now a ...

PCORI also is offering up to $200 million through the Phased Large Awards for Comparative Clinical Effectiveness Research (PLACER) PFA, for ambitious, large-scale two-phased trials addressing critical ...

The Purdue University Board of Trustees has approved the naming of the Evan and Sue Ann Werling Comparative Oncology Research Center in recognition of the donors’ $10 million gift. The center, part of ...

The importance of science advice—broadly defined here as practices for mobilizing scientific knowledge in support of public decision-making—is now widely accepted (OECD, 2015). Over the last decade, ...